TLPH — Talphera, Inc.
$0.91
$-0.13 (-12.46%)
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
Market Cap
$47.03M
Forward P/E
-4.1x
52-Week Range
N/A
TLPH Price History
Revenue vs. Net Income
$28K
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
-$11.4M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-55.4%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
2.3x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
15.4%
CapEx · FY2023
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+64.1%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
